Key result
Drug-coated balloon treatment for coronary lesions in patients >80 years old showed no significant difference in major adverse cardiovascular events compared to patients <70 years old (p=0.225).
Why the study?
DCBs potentially shorten DAPT duration, which could benefit elderly patients, but their safety and efficacy for coronary lesions in this population compared with younger patients required investigation.
Does drug-coated balloon inflation for coronary lesions have similar safety and efficacy in elderly patients (>80 years) compared to younger patients (<70 years)?
Cohort (n=446)
No
Does drug-coated balloon inflation for coronary lesions have similar safety and efficacy in elderly patients (>80 years) compared to younger patients (<70 years)?
p-value: p=0.225
Drug-coated balloons appear to be as safe and effective for treating coronary lesions in elderly patients (>80 years) as in younger patients, which may facilitate shorter dual antiplatelet therapy durations.
May support DCB consideration in elderly coronary patients; leaves open need for randomized age-specific confirmation.
Introduction: The use of drug-coated balloons (DCBs) has become more prevalent in the past few years for the treatment of in-stent restenosis (ISR) and de novo lesions. The absence of foreign polymer implantations potentially shortens the duration of dual anti-platelet therapy (DAPT), which can be beneficial for the elderly population. We aimed to investigate the safety and efficacy of the use of DCBs for the treatment of coronary lesions in elderly patients as compared to the younger population. Materials and methods: A database of 446 consecutive patients who underwent a procedure of DCB inflation in our institution was divided into two groups, below 70 years old and above 80 years old. We compared and analyzed the endpoints of total major adverse cardiovascular events (MACE), cardiovascular (CV) death, and all-cause mortality in both groups. Results: The difference in MACE between the two age groups was non-significant (p = 0.225); the difference in cardiovascular death was also non-significant (p = 0.086). All-cause mortality was significantly different (p < 0.0001) and can be attributed to the age of the patients. Conclusion: The utilization of DCBs for the treatment of coronary lesions may be as safe and effective for the elderly population as for the younger population and may allow a shorter period of DAPT therapy, which can lower the risk of bleeding.
No takes yet. Share an insight, caveat, or question.
Sella et al. (2022) conducted a cohort in Coronary lesions (n=446). Drug-coated balloons in patients >80 years old vs. Drug-coated balloons in patients <70 years old was evaluated on Total major adverse cardiovascular events (MACE) (p=0.225). Drug-coated balloon treatment for coronary lesions in patients >80 years old showed no significant difference in major adverse cardiovascular events compared to patients <70 years old (p=0.225).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: